Value Picks: Uncovering Hidden Investment Gems

Value Investor’s Deep-Dive (October 15, 2025)

A research-first scan of 10 candidates, followed by a full valuation on the most compelling idea today. No hype—just numbers, drivers, and risks.


Shortlist: 10 Value Candidates Worth Attention

  1. Verizon (VZ)
  • Why now: Healthy free cash flow (FCF) and rising 2025 guidance after network investments; dividend support looks solid. (verizon.com)
  1. Pfizer (PFE)
  • Why now: Post-COVID reset largely digested; 2025 guidance suggests margin rebuild amid cost cuts; valuation depressed vs. history. (pfizer.com)
  1. Medtronic (MDT)
  • Why now: Improving margin and FCF, 48th straight dividend hike, and planned diabetes separation to simplify the story. (news.medtronic.com)
  1. CVS Health (CVS)
  • Why now: Pharmacy/benefits cash engine with managed-care headwinds being reset (premium deficiency reserve recognized). Multiple remains subdued. (investors.cvshealth.com)
  1. Intel (INTC)
  • Why now: High-risk turnaround; 18A ramp and U.S. fab progress are real but require flawless execution and foundry wins. Deep value if it works. (barrons.com)
  1. Micron (MU)
  • Why now: Memory upcycle and HBM demand; strong margin/FCF inflection through FY25. Cyclical—value depends on mid-cycle normalized earnings. (investors.micron.com)
  1. Berkshire Hathaway (BRK.B)
  • Why now: Fortress balance sheet and optionality; not “cheap,” but quality at a fair price with record cash. (nasdaq.com)
  1. Alphabet (GOOGL)
  • Why now: Low- to mid-teens P/E for a dominant franchise; capex surge weighs on near-term FCF but builds durable AI infrastructure. (cnbc.com)
  1. Meta (META)
  • Why now: Strong FCF and engagement; capex heavy, but ROI could be high if AI bet pays. Not a classic “deep value,” more “quality compounder at a reasonable price.” (reuters.com)
  1. Cardinal Health (CAH)
  • Why now: Durable pharma distribution economics, growing specialty exposure, improving medical profitability, and visible EPS/FCF outlook. Valuation still below peers on many metrics. (newsroom.cardinalhealth.com)

Pick: Cardinal Health (CAH)

I’m selecting Cardinal Health as the best value candidate today. It offers:

  • Predictable cash flows from scale distribution
  • Expanding specialty platforms (GI Alliance stake, oncology services) with higher margins
  • Strengthening medical segment execution
  • Clear guidance for FY26 EPS and FCF
  • Still-reasonable multiples vs. direct peers McKesson and Cencora

At today’s price of $155.78, market cap ~$37B (using ~239M diluted shares guided for FY26). That sets the stage for a clean, conservative valuation. (newsroom.cardinalhealth.com)


Business Snapshot

  • Core: U.S. pharma distribution (brand and specialty), plus medical products and logistics (GMPD) and “Other” (at-Home Solutions, Nuclear/Precision Health, OptiFreight).
  • 2025–2026 road map: Push deeper into specialty (GI Alliance majority stake; ION), scale at-Home Solutions and logistics, drive medical profitability, and return more cash via buybacks.
  • FY25/FY26 visibility:
    • FY25 EPS raised to $8.05–$8.15; FY26 EPS raised to $9.30–$9.50 (13–15% growth).
    • FY26 adjusted FCF targeted at $2.75–$3.25B; capex ~$600M; buybacks ~$750M.
    • Shares guided: ~238–240M. (newsroom.cardinalhealth.com)

Competitive landscape: Oligopoly with McKesson and Cencora—scale, working-capital velocity, and purchasing leverage matter most. Specialty mix and services add incremental margin. GLP‑1s shift mix but flow through the channel; distributors earn pennies on the dollar of gross billings, so volume and product complexity matter more than unit price. (reuters.com)


What Can Go Wrong (Key Risks)

  • Contract churn/renegotiations can ding segment profit even when revenue optics are flat.
  • GLP‑1 and biosimilar dynamics can change mix; execution in medical must hold.
  • Narrow margins require tight operations; small errors can matter.
  • Interest expense and working-capital swings can move near-term FCF. (newsroom.cardinalhealth.com)

Valuation Deep-Dive

1) Ground-up DCF (all numbers in $ billions unless noted)

Starting point and base facts (management-guided where available):

  • FY26 non-GAAP EPS: $9.40 midpoint on ~239M shares ⇒ ~$2.25B non-GAAP net income proxy.
  • FY26 adjusted FCF: $2.75–$3.25B; we use $3.0B midpoint as Year 1 FCF.
  • Capital intensity low; capex guided ~$0.6B; working capital generally modestly positive over a cycle. (newsroom.cardinalhealth.com)

Assumptions (explicit and conservative):

  • Year 1 (FY26) FCF: $3.0B (management midpoint).
  • FCF growth years 2–5: 5.0% CAGR (mix shift to specialty, execution in medical, modest buybacks).
  • Years 6–10: 3.0% CAGR (matures with U.S. drug-spend growth near nominal GDP + specialty).
  • Terminal growth (G): 2.0% (below nominal GDP).
  • Discount rate (WACC): 8.5% base; test 8.0–9.5% in sensitivity.
  • Net debt/other: Use FCF-based equity valuation; management targets ~neutral working-cap effects over cycle. (For a conservative tilt, we haircut terminal value via higher WACC in downside case.)

Step-by-step:

  • Years 1–5 FCF (B):

    • Y1: 3.00
    • Y2: 3.15
    • Y3: 3.31
    • Y4: 3.48
    • Y5: 3.65
  • Years 6–10 FCF at 3% growth:

    • Y6: 3.76
    • Y7: 3.87
    • Y8: 3.99
    • Y9: 4.11
    • Y10: 4.23
  • Terminal value at end of Y10 (Gordon): TV = FCF10 × (1+G)/(WACC–G)

    • TV = 4.23 × 1.02 / (0.085 – 0.02) ≈ 4.31 / 0.065 ≈ 66.3
  • Present value at 8.5%:

    • PV of Y1–Y10 FCF ≈ 22.9
    • PV of TV ≈ 29.9
    • Enterprise value (FCF to equity) ≈ 52.8
  • Equity per share (239M shares): ≈ $221 per share.

Sensitivity (per-share equity value):

  • WACC 8.0%, G 2.0% ⇒ ~$240
  • WACC 9.0%, G 1.75% ⇒ ~$200
  • WACC 9.5%, G 1.5% ⇒ ~$182

DCF fair value range (rounded): $180–$240, base case ≈ $220.

Cross-check vs. guidance: The model anchors on management’s FY26 FCF midpoint and assumes mid-single-digit growth—reasonable given specialty growth and operating discipline. (newsroom.cardinalhealth.com)

2) Comparables (quick and clean)

  • Peers: McKesson (MCK), Cencora (COR). At today’s prices, market is granting premium multiples to the best-executing distributors; CAH trades at a discount on forward P/E using FY26 EPS ($9.30–$9.50).

    • CAH forward P/E ≈ 16.4–16.8x at $155.78.
    • Peer premiums reflect mix and execution, but CAH’s improving trajectory and higher FCF conversion argue for multiple convergence.
  • EV/FCF lens: FY26 FCF midpoint $3.0B on ~$37B market cap implies an ~8% FCF yield—attractive for an oligopoly distributor with visible growth. (newsroom.cardinalhealth.com)


Investment View

  • Thesis: CAH’s distribution moat + rising specialty/services + improving medical execution = resilient and growing FCF.
  • Valuation: DCF base ~$220 per share; downside (higher WACC/lower terminal) ~$180; upside with faster specialty growth or additional buybacks ~$240+.
  • Margin of safety: At $155–$160, the setup offers roughly 15–40% upside to fair value, plus a modest dividend.
  • What would change my mind: Major customer loss, unexpected margin compression in medical, or a reversal in specialty growth.

Bottom line: Buy for long-term value investors willing to own a steady FCF compounder with an improving mix and credible FY26 targets.


Why Other Candidates Didn’t Win Today

  • Verizon: Solid FCF guidance and dividend, but secular growth is lower; upside less compelling than CAH’s rerating potential. (verizon.com)
  • Pfizer: Pipeline and margin rebuild are real, but headline risk remains high; need more proof of durable non-COVID growth. (pfizer.com)
  • Medtronic: Attractive, but diabetes separation execution risk and slower top-line vs. CAH’s specialty acceleration. (news.medtronic.com)
  • CVS: Still resetting medical-cost trend; value is there but more moving parts. (investors.cvshealth.com)
  • Intel: Big upside if foundry lands; risk/reward is more “speculative deep value” than classic value today. (barrons.com)
  • Micron: Great cycle, but not a classic value at this point in the upcycle. (investors.micron.com)
  • Berkshire: High quality, less mispriced. (nasdaq.com)
  • Alphabet/Meta: Reasonable valuations for giants, but capex overhang and market appreciation limit “value” upside vs. CAH. (cnbc.com)

Positioning Notes

  • Sizing: For a diversified value portfolio, CAH could fit as a 3–5% core position, scaled up on pullbacks toward $145 and trimmed >$210 if rerating happens quickly.
  • Time horizon: 2–4 years to realize mix/medical improvements and multiple convergence.

References and Primary Sources

  • Cardinal Health FY25–FY26 results, guidance and segment details:

  • Market data (as of October 15, 2025):

    • CAH, MCK, COR quotes [market data]
  • Peers and other candidates:

    • Verizon 2025 guidance (EBITDA/EPS/FCF) [verizon.com] (verizon.com)
    • Pfizer 2025 guidance [pfizer.com] (pfizer.com)
    • Medtronic FY25 results, dividend, separation plan [news.medtronic.com] (news.medtronic.com)
    • CVS Q2 2025 and premium deficiency reserve [investors.cvshealth.com] (investors.cvshealth.com)
    • Intel 18A/Panther Lake progress [barrons.com; reuters.com; ft.com] (barrons.com)
    • Micron FY25 trajectory and HBM [investors.micron.com; investing.com] (investors.micron.com)
    • Berkshire cash/positioning [nasdaq.com] (nasdaq.com)
    • Alphabet capex and AI infrastructure context [cnbc.com; fool.com] (cnbc.com)
    • Meta data center expansion [reuters.com] (reuters.com)

Note: This is investment research and not investment advice. Please consider your objectives, risk tolerance, and constraints before acting.